SEC Form 4 · accession 0001562180-16-003314
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Albert Robichaud
Officer — Chief Scientific Officer
Period of report
Oct 28, 2016
Accepted (ET)
Nov 1, 2016 · 2:55 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 28, 2016 | M | 15,287 | $1.36 | A | 155,509 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.36 | Oct 28, 2016 | M | 15,287 | D | — | Jan 24, 2024 | Common Stock | 15,287 | 6,935 | D |
Explanation of responses
- F1Shares vest evenly spread over 48 months beginning on 01-Feb-2014.